Could a common ED drug help fontan hearts? new trial aims to find out

NCT ID NCT05206955

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether tadalafil, a drug that relaxes blood vessels, can improve blood flow and protect organs in adults who had Fontan surgery for a single-ventricle heart defect. About 80 participants will receive either tadalafil or a placebo daily for a year. Researchers will measure changes in blood vessel function, liver stiffness, kidney function, and exercise capacity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tadalafil

What this could lead to

If it works, this could lead to a new treatment to improve blood flow and protect the liver, kidneys, and exercise ability in people living with Fontan circulation.

What could go wrong

This is a phase 3 trial, but tadalafil has not been proven effective for this condition before. It may not improve outcomes, and side effects like headache or muscle aches are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FONTAN PALLIATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact